INTRODUCTION

COVID-19 is a beta coronavirus, which has now spread extensively all over the world after its novel outbreak from December 31, 2019.1 Common neurological manifestations of COVID-19 include headache, dizziness, seizures, stroke, neuralgia, encephalitis, and hypogeusia.2,3

Guillain-Barré syndrome (GBS) is an immunemediated, postinfectious neuropathy characterized by progressive, symmetrical, and ascending weakness, with hyporeflexia or areflexia and with or without cranial nerve involvement.4,5 Autonomic dysfunctions and sensory symptoms may or may not be present.5 Although the first reported case of GBS in Wuhan was proposed to be a parainfectious manifestation, it has also been reported as a rare but possible consequence of COVID-19.6-9 We report a case of GBS in a patient infected with COVID-19 in Nepal.

CASE PRESENTATION

A 68-year-old man presented in the emergency, with acute symmetric progressive ascending quadriplegia, tingling sensation of the lower extremities, and dysphagia. Reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was tested positive subsequently in the emergency department. Ten days prior to this, the patient had symptoms of myalgia, rhinorrhea, dysgeusia, and fever lasting for 5 days. After 5 days of his recovery, the patient suddenly developed difficulty in bearing weight in lower limbs while he woke up in the morning. Next day, he had difficulty holding food in his hands, though was able to feed by himself. Two days later he developed tingling, pin, and needle sensations over his lower extremities and lips. His weakness was also gradually worsening till 7 days after the onset of symptoms.
During the presentation in emergency, the patient was bed-bound and needed help for feeding and other functional activities. There was no swallowing difficulty and shortness of breath. Bowel and bladder were normal, and the patient is not diabetic.

On physical examination, the patient was conscious, afebrile with blood pressure measuring 160/100 mmHg, heart rate 100 beats/min, respiratory rate of 20 breaths/min, and oxygen saturation of 93 percent on room air. Facial nerve examination showed bilateral lower motor neuron type palsy (House-Brackmann grade 3). Other cranial nerves were intact. No signs of meningeal irritation were present. Muscle strength examination showed a Medical Research Scale (MRC) of 2/5 in proximal, 3/5 in distal of upper extremities, 1/5 in proximal, and 2/5 in distal of lower extremities. Deep tendon reflexes were absent in all limbs. There was normal fine touch, pain, temperature, and vibration sensation in both upper and lower extremities.

The blood investigation results were as follows: total leukocyte count 8400/mm³ (neutrophils 72% and lymphocytes 24%); hemoglobin 14.2 g/dl; red blood cell 4.8 million/mm³; platelets 371,000/mm³; random sugar 6.7 mmol/L; sodium 135 mEq/L; potassium 3.6 mEq/L. His renal and hepatic tests were within normal range. His prothrombin time was 13 s; prothrombin international normalized ratio 0.98; activated partial thromboplastin time 26.4 s; fibrinogen 432 mg/dl; fibrin degradation product (FDP) D-dimer 0.36 mg/ml; and ferritin 382 µg/ml. Chest X-ray and electrocardiograph findings were normal. Other laboratory tests including human immunodeficiency virus, syphilis, hepatitis B and C, and thyroid function test were unremarkable.

Eight days after the admission in COVID ward, the patient was shifted to the general ward. Cerebrospinal fluid analysis results showed a total leukocyte count of 5 cells (polymorph 0% and lymphocyte 100%), sugar 3.5 mmol/L, and protein 130 mg/dl. Due to unavailability of nerve conduction study in the inpatient settings, it could not be performed then.

With the strong clinical suspicion of Guillain-Barré syndrome, the patient received 400 mg/kg/day intravenous immunoglobulin (IVIg) for 5 days while being admitted in the COVID ward. He also received gabapentin 300 mg two times a day for paresthesia in lower limbs. Patient’s weakness of limbs gradually improved after IVIg treatment. During discharge, motor power of upper limbs improved to MRC of 4+ and 4 in lower limbs. In follow-up in 1 month, weakness further improved and the patient is now able to walk without support and can do all his daily activities with only mild difficulties.

### 3 DISCUSSION

Respiratory symptoms like fever, difficulty in breathing, and cough are common manifestations due to the infection by beta coronaviruses, but neurological symptoms have also been reported. Study by Mao et al. in Wuhan, China, has reported neurological symptoms in hospitalized patients with COVID-19 with the conclusion of neurological manifestations being seen commonly in the patients with more Spartan COVID-19 illness. Our patient satisfies the level 2 diagnostic certainty of Brighton criteria for GBS with all the features except the nerve conduction findings, which was not performed in our case. The Brighton diagnostic criteria for GBS can be found in Table 1.

Prior to GBS findings, our case had a characteristic course of viral symptoms for 5 days. Meanwhile, the duration of onset of viral illness and neurological manifestations has ranged from 5 to 24 days. Five cases of

| TABLE 1 Brighton diagnostic criteria for GBS³⁴ |
|---------------------------------------------|
| **Diagnostic criteria**                     | **Level of diagnostic certainty** |
|                                            | Level 1 | Level 2 | Level 3 | Level 4 |
| The absence of alternative diagnosis for weakness | +      | +      | +      | +      |
| Diminished or absent deep tendon reflex in weak limbs | +      | +      | +      | +/−    |
| Monophasic course and time between onset and nadir, 12 h to 28 days | +      | +      | +      | +/−    |
| Bilateral and flaccid weakness of limbs | +      | +      | +      | +/−    |
| CSF cell count <50 cells/µl | +      | +      | −      | +/−    |
| CSF protein concentration > normal value | +      | +/−    | −      | +/−    |
| NCS findings consistent with one of the subtypes of GBS | +      | +/−    | −      | +/−    |

Note: +: present; −: absent; +/−: present or absent.

Abbreviations: CSF, cerebrospinal fluid; GBS, Guillain-Barré syndrome; NCS, nerve conduction study.

³If CSF is not collected or results not available, nerve electrophysiology results must be consistent with the diagnosis Guillain-Barré syndrome.
COVID-19 developing GBS 5–10 days after infection were reported by Toscano et al.7 However, simultaneous occurrences of respiratory and neurological symptoms have also been reported.15,16 In Iran, three patients were diagnosed with GBS during the active phase of COVID-19.17

Our patient did not have respiratory failure and also did not require mechanical ventilation during the course of his hospital stay. A meta-analysis summarizing 42 cases of GBS in the setting of COVID-19 from January to August of 2020 reported 14 of these patients had respiratory failure, and 12 of them required mechanical ventilation.18 With some overlap in the included studies, another meta-analysis presented 61 cases of GBS associated with COVID-19, of which 23 needed intensive care unit (ICU) admission, with 17 requiring mechanical ventilation.19 Furthermore, a systematic review comprising 12 patients described five patients having symptom remission or mild persistent symptoms, four of them requiring critical care and one death.20

Guillain-Barré syndrome is an immune-mediated disorder triggered by an infection or immune stimulus with the initiation of an uncharacteristic immune reaction to peripheral nerves as a result of molecular mimicry.21 COVID-19 creates an immune-mediated course due to stimulation of various inflammatory cells and thereby leading to production of inflammatory cytokines.22 It is still uncertain whether GBS due to COVID-19 is due to antibody production against specific gangliosides as seen in some forms of GBS or T-cell-mediated actions or straight neuroinvasive events.23,24 There is a need for further investigations about the development of GBS in patients with COVID-19.

ACKNOWLEDGEMENTS
We gratefully acknowledge the work of members of our hospital and the patient.

CONFLICT OF INTEREST
The authors declare that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS
(RO) Rajeev Ojha, (BPG) Bikram Prasad Gajurel, (RK) Ragesh Karn, (RR) Reema Rajbhandari, (SP) Sunanda Paudel, (NG) Niraj Gautam, and (AS) Ashish Shrestha involved in the patient care team and contributed to the collection of case information. (RO) Rajeev Ojha contributed to conceptualization and editing of the manuscript. (RA) Roshan Aryal, (SK) Shivaji Karki, and (SR) Shreesti Rajbhandari collected all the required case information and reports and reviewed the literature and contributed in writing and editing the manuscript. All authors read and approved the final manuscript.

ETHICAL APPROVAL
This study did not include experiments on animals or humans. The patient gave consent to use his details for this case study.

CONSENT
Written informed consent was obtained.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author, upon reasonable request.

ORCID
Roshan Aryal @ https://orcid.org/0000-0002-4689-9264
Bikram Prasad Gajurel @ https://orcid.org/0000-0002-9995-0705
Niraj Gautam @ https://orcid.org/0000-0002-1675-0493
Rajeev Ojha @ https://orcid.org/0000-0001-7680-7036

REFERENCES
1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401-402.
2. Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis. 2020;36:101642.
3. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270.
4. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133. doi:10.1159/000324710
5. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21-S24.
6. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383-384. doi:10.1016/s1474-4422(20)30109-5
7. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-2576.
8. Riva N, Russo T, Falzone YM, et al. Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report. J Neurol. 2020;267(9):2492-2494.
9. Chan JL, Ebadi H, Sarna JR. Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci. 2020;47(6):852-854.
10. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194:105921.
11. Sahin AR, Erdogan A, Aqaoglu PM, et al. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. Eurasian J Med Oncol. 2020;4(1):1-7.
12. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a
13. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. *Brain*. 2014;137(Pt 1):33-43.

14. Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. *Rev Neurol (Paris)*. 2020;176(6):516-518. doi:10.1016/j.neurol.2020.04.003

15. Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflamm*. 2020;7(4):e741. doi:10.1212/NXI.0000000000000741

16. Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. *IDCases*. 2020;20:e00771.

17. Abolmaali M, Heidari M, Zeinali M, et al. Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series. *J Clin Neurosci*. 2021;83:119-122.

18. Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis. *J Peripher Nerv Syst*. 2020;25(4):335-343.

19. Uncini A, Vallat JM, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. *J Neurol Neurosurg Psychiatry*. 2020;91(10):1105-1110.

20. Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA. COVID-19 and Guillain-Barre syndrome: a systematic review of case reports. *Wellcome Open Res*. 2020;5:107.

21. Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. *Neurology*. 1998;51(4):1110-1115. doi:10.1212/wnl.51.4.1110

22. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.

23. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol*. 2020;92(6):552-555.

24. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. *J Clin Neurosci*. 2020;76:233-235.

How to cite this article: Aryal R, Karki S, Rajbhandari S, et al. Guillain-Barré syndrome associated with Coronavirus disease 2019: A case from Nepal. *Clin Case Rep*. 2022;10:e05638. doi:10.1002/ccr3.5638